Identifying novel and known genes that are dierentially expressed in breast cancer has important implications in understanding the biology of breast tumorigenesis and developing new diagnostic and therapeutic agents. In this study we have combined two powerful technologies, PCRbased cDNA subtraction and cDNA microarray, as a high throughput methodology designed to identify cDNA clones that are breast tumor-and tissue-speci®c and are overexpressed in breast tumors. Approximately 2000 cDNA clones generated from the subtracted breast tumor library were arrayed on the microarray chips. The arrayed target cDNAs were then hybridized with 30 pairs of¯uorescent-labeled cDNA probes generated from breast tumors and normal tissues to determine the tissue distribution and tumor speci®city. cDNA clones showing overexpression in breast tumors by microarray were further analysed by DNA sequencing, GenBank and EST database searches, and quantitative real time PCR. We identi®ed several known genes, including mammaglobin, cytokeratin 19, ®bronectin, and hair-speci®c type II keratin, which have previously been shown to be overexpressed in breast tumors and may play an important role in the malignance of breast. We also discovered B726P which appears to be an isoform of NY-BR-1, a breast tissue-speci®c gene. Two additional clones discovered, B709P and GABA A receptor p subunit, were not previously described for their overexpression pro®le in breast tumors. Thus, combining PCRbased cDNA subtraction and cDNA microarray allowed for an ecient way to identify and validate genes with elevated mRNA expression levels in breast cancer that may potentially be involved in breast cancer progression. These dierentially expressed genes may be of potential utility as therapeutic and diagnostic targets for breast cancer.
Introduction
Breast cancer is one of the most common malignancies and a leading cause of death among women. There are 200 000 new cases diagnosed every year and about 50 000 women die annually from breast cancer in the United States (Lopez-Otin and Diamandis, 1998) . Although localized breast cancer can be eectively treated, the prognosis of breast cancer is poor and there are a very limited number of treatment options available for patients with advanced and metastatic forms of the disease. Thus, there is a clear need to ®nd new targets for the development of new therapeutic agents as well as breast tumor markers for monitoring both progression and treatment of the disease.
Genetic alterations resulting in altered mRNA and protein levels have been described in breast tumorigenesis, such as the activation or ampli®cation of oncogenes or the loss of tumor suppressor genes (Jones et al., 1995; Walker et al., 1997) . Historically, a number of these genes have been identi®ed such as Her-2/neu, a surface growth factor receptor shown to be overexpressed in 30% of breast cancers (Hadden, 1999; Disis and Cheever, 1997) . The p53 gene that normally functions as a tumor suppressor gene has been found to be paradoxically overexpressed in 57% of breast tumors as an outcome of gene mutation and changes in protein stabilization (Hadden, 1999) . MUC-1 is another gene that is up regulated about 10-fold in 90% of breast tumors (Hadden, 1999; McKenzie and Xing, 1990) . Each of these proteins has become the target for novel immunotherapy approaches in the treatment of breast cancer (Cheever et al., 1995; Ozturk et al., 1992; Apostolopoulos et al., 1996) . It should be noted, however, that all genes mentioned above show expression in some normal tissues that could cause toxicity and non-speci®city when used as therapeutic and diagnostic agents. Furthermore, breast cancer is a disease with extreme complexity (Lopez-Otin and Diamandis, 1998; Jones et al., 1995; Walker et al., 1997) . Identifying additional genes that may be up-or down-regulated in breast tumors will help us to better understand the process of breast tumorigenesis and provide additional markers for treatment and diagnosis of the disease.
Suppression subtractive hybridization (SSH) technology, also known as PCR-based cDNA subtraction, was developed by Diatchenko et al. (1996) . This method allows selective ampli®cation of target cDNAs, while simultaneously suppressing non-target cDNA ampli®-cation. An advantage of the PCR-based cDNA subtraction method is that in addition to the recovery of abundant clones regularly obtained by conventional cDNA subtraction (Xu et al., 2000) , rare transcripts are also recovered due to the incorporated hybridization and PCR steps that normalize sequence abundance. As a result, the subtracted cDNA library generated by SSH technology contains an increased number of dierentially expressed genes. Recent advances in technology, especially in the area of high-density cDNA microarrays (Schena et al., 1995 (Schena et al., , 1996 DeRisi et al., 1997) , have allowed us to simultaneously monitor the gene expression pro®les of thousands of genes, thereby providing a way to rapidly identify genes up-regulated in breast cancers.
In this study our goal was to identify breast tumorand tissue-speci®c genes as targets for immunotherapy. Historically, the development of immunotherapy of cancer was focused on the induction of immune responses against tumor-speci®c antigens, since theoretically, immune responses targeted to tumor-speci®c antigens would be exclusively against the tumor and would cause no damage to the normal cells. Also one could reasonably presume that self-tolerance to tumorspeci®c antigens could be broken more easily than to tissue-speci®c self-antigens. In 1994 Coulie et al. discovered that a melanoma-speci®c CD8 + T cell clone grown from a melanoma patient was against wild-type tyrosinase, a melanocyte speci®c gene (Coulie et al., 1994) . Subsequently, a number of similar ®ndings that these melanoma-speci®c CD8 + T cells indeed recognized melanocyte-speci®c antigens rather than melanoma-speci®c antigens were published (Bakker et al., 1994; Cox et al., 1994; Kawakami et al., 1994) . Based on these ®ndings and given that breast tissues are dispensable, inducing immune responses against tissuespeci®c antigens might represent a reasonable approach for breast cancer therapy whose autoimmune side eects would be acceptable. We utilized SSH technology and cDNA microarray as an initial high throughput screen followed by quantitative real time PCR analysis to discover genes that are overexpressed in breast tumor and/or breast normal tissues. Here we report on four genes, B709P, hair-speci®c type II keratin, B726P, and GABA a receptor p subunit, which are overexpressed in primary and metastatic breast tumors.
Results

Characterization of the subtracted cDNA library
Poly(A) + RNAs from three primary breast tumors were used as the starting material for tester cDNA synthesis. In order to identify breast tumor-and tissuespeci®c sequences, mRNAs from a variety of normal tissues and cells including breast, brain, liver, pancreas, and peripheral blood mononuclear cells (PBMC) were utilized for driver cDNA synthesis. The library was constructed according to the established protocol (Clontech Inc. CA, USA) with modi®cations. In the original procedure, the tester and driver cDNAs were digested with RsaI, a four base-pair DNA endonuclease, creating cDNA fragments with an average size of 256 bp. To maximize the sensitivity of the cDNA microarray under the hybridization conditions used, we chose to increase the average size of the cDNA fragments. To accomplish this, we substituted RsaI with a combination of ®ve six-base cutter DNA endonucleases. Theoretically, the average cDNA size after digestion with this group of enzymes is 819 bp. We analysed 96 randomly selected clones from the subtracted library and the average cDNA insert size was approximately 650 bp (data not shown). Subtraction eciency was determined by two methods: dot blot and DNA sequencing. We found that about one third of the 96 randomly selected clones showed positive hybridization to the tester probes, while only a few clones showed positive hybridization to the driver probes. All the clones showed up positive with subtracted cDNA probes (data not shown). We next performed DNA sequencing analysis of these 96 clones, which revealed several genes that are known to be overexpressed in breast tumors (Table 1) . These genes are mammaglobin (Watson and Fleming, 1996) , keratin (Trask et al., 1990) , and estrogen receptor (Kurebayashi et al., 2000) . Of the 96 clones examined, four clones did not match any entry (550% identity) in the public databases including GenBank DNA and human EST. Additionally, forty clones were found to have no GenBank matches but did exhibit signi®cant homology (498% identity) to one or more human ESTs. Furthermore, relatively few housekeeping genes were recovered and most of the clones were represented only once in this 96 clone set. Collectively, these data suggested that the library was well subtracted and normalized, and contained sucient complexity to exploit cDNA microarray analysis.
cDNA microarray analysis
A total of two thousand randomly selected cDNA clones generated by PCR-based cDNA subtraction were analysed by microarray with 30 probe pairs. The probes consisted of 22 primary breast tumor samples; three breast tumors metastasized to lymph nodes, three breast tumor pleural eusion samples, two normal breast tissue samples, and 30 samples from a variety of human normal essential tissues. In most cases, a breast tumor was paired randomly with a normal tissue. The average¯uorescent intensity of all probes generated from breast tumors including metastatic breast tumors was compared with the average¯uorescent intensity of all the normal tissues excluding normal breast tissues. Sixty-two clones with a ratio between these two probe groups (all breast tumors vs all normal non-breast tissues) greater than three were selected and sequenced, as shown in Table 2 . Among these clones there were 31 known genes including mammaglobin, 40 kDa keratin, and ®bronectin, which have previously been shown to be associated with breast cancers (Watson and Fleming, 1996; Loridon-Rosa et al., 1990; Trask et al., 1990) .
Identification of cDNAs differentially expressed in breast tumor
The 62 clones with larger than threefold overexpression in breast tumors were further analysed by examining the microarray pro®le of each individual clone for its expression in each probe pair tested in order to identify clones that are overexpressed in breast tumors vs normal tissues including normal breast (tumor-speci®c) and clones overexpressed in breast tumors vs normal non-breast tissues (tissue-speci®c). We looked for clones that had a strong signal (breast tumor signal vs paired normal tissue signal is equal to or greater than three) in multiple breast tumor samples (at least 20% of breast tumors) while having very little or no signal in the majority of the normal non-breast tissue samples. Based on these criteria, we selected four clones which had the best breast tumor/tissue-speci®c expression pro®le for further characterization. The four clones selected were not necessarily the clones with the highest tumor/normal ratio, but rather the ones with the cleanest expression pro®le in the normal non-breast tissues. Figure 1 shows the microarray pro®les of these four genes discovered from the DNA microarray chip: B709P, B726P, hair speci®c type II keratin, and GABA A receptor p subunit. It is evident from the microarray pro®le that these genes are overexpressed in breast tumors and/or normal breast tissues compared to other normal tissues. Another characteristic is that while each of the four genes is expressed in a dierent subset of the breast tumor panel, there is complementation such that, taken together, expression of these four genes shows threefold upregulation in 64% (18 out of 27) of the breast tumor samples (Houghton et al., 2001) .
The cDNA microarray results indicated that B709P is at least threefold overexpressed in approximately 20% of the breast tumors. The two normal breast and human epithelial mammary gland cell (HEMC) samples showed no expression. B709P also showed some expression in normal lymph node, trachea, and salivary gland. Other normal tissues, such as brain, heart, pancreas, liver, kidney, and bone marrow did not show any expression on the array (Figure 1 ). The average overexpression ratio of B709P in breast tumors vs non-breast normal tissues is 3.1 ( Table 2 ). The full length B709P cDNA was recovered from a breast tumor oligo(dT)-primed cDNA library by hybridization screening using the original cDNA fragment generated from the subtracted breast tumor library as a probe. Complete sequencing of B709P resulted in a 491 bp sequence encoding an 85 amino acid predicted open reading frame (ORF) (Figure 2 ). PSORT, a program for protein localization prediction, predicted B709P to be a secreted protein with a 17 amino-acid signal peptide sequence for secretion at its amino terminal end. The cDNA sequence of B709P is identical to full length insert cDNA clone ZA74F12 in the GenBank nonredundant DNA database (Accession number AF086120). A BlastP search of the GenBank protein database failed to reveal any signi®cant matches. This protein has a high proline content comprising about 20% of its coding sequence.
The second gene identi®ed was the human hairspeci®c type II keratin gene (hHb1). Microarray data showed that hHb1 has at least threefold overexpression in approximately 30% of breast tumors compared to the paired normal tissues. Additionally, some expression was observed in human mammary epithelium cells. Signi®cantly, hair-speci®c type II keratin expression was not seen in normal breast or any other normal tissues examined ( Figure 1 ). The average overexpression of hHb1 in breast tumors vs non-breast normal tissues is 3.5 ( Table 2 ). The hHb1 gene is located on the q11-q13 region of chromosome 12 where the type II keratin cluster resides (Bowden et al., 1998) . It has been demonstrated that hHb1 is abundantly expressed in the dierentiating cortex of growing hair (Bowden et al., 1998) . Additionally, Regnier et al. (1998) have demonstrated that a truncated version of the hHb1 gene, which is missing about 800 base pairs of DNA at the 5' end, is expressed in human breast carcinomas. We have found both full length and truncated forms of hHb1 gene in breast tumors.
The third gene, B726P, was at least threefold overexpressed in 36% of breast tumors and was also expressed at a lower level in one of two normal breast tissues by cDNA microarray analysis. In two breast tumor samples, B726P has a greater than 20-fold increase in expression compared to the paired normal tissues (Figure 1 ). The average overexpression of B726P in breast tumors vs non-breast normal tissues is 3.6 (Table 2) . Full-length cloning eorts resulted in a 3681 base pair cDNA and a GenBank database search with this sequence revealed that B726P matched to NY-BR-1, which was recently identi®ed by using serological analysis of recombinant expression libraries (SEREX) method and was predicted to function as a transcription factor based on its motif (Jager et al., 2001) . B726P also has several matching EST hits from normal breast, breast tumor, and testis. Multiple mRNA splice forms exist for this gene, which generate putative ORFs of 1002 amino acids, 650 amino acids, and 317 amino acids (Harlocker et al. manuscript in preparation). The predicted 317 amino-acid sequence shares a 42% homology with a hypothetical protein of unknown function in GenBank, KIAA0565 (GenBank accession number BAA25491). The longest predicted 1002 amino acid ORF is identical to amino acid 340 to 1341 of NY-BR-1.
The cDNA microarray also identi®ed g-aminobutyric acid (GABA a ) receptor p subunit as an overexpressed gene in breast tumors and normal breast tissues. This protein was ®rst reported as a novel subtype of the 
GABA A receptor subunit, sharing 30 ± 40% amino acid homology with other GABA A family members (Hedblom and Kirkness, 1997) . The microarray data indicated that approximately 30% of the breast tumors examined have more than threefold overexpression. We also detected some GABA A receptor p subunit expression in normal breast, uterus, and trachea ( Figure 1 ). The average overexpression of GABA a receptor p subunit in breast tumors vs non-breast normal tissues is 4.0 (Table 2) . GABA a receptors were shown to be located on central neurons and astroglia, and were also detected on non-neuronal cells including endocrine cells of the pituitary pars intermediate and smooth muscle cells of the urinary bladder and uterus (Amenta et al., 1988; Erdo et al., 1989) . The function of GABA A receptors in non-neuronal cells is not clear, although their function in the uterus appears to be related to the regulation of uterine motility by inhibiting contraction (Majewska and Vaupel, 1991) . The expression of the p subunit of GABA A at the mRNA level has been shown to be present at low levels in prostate, ovary, placenta, gall bladder, lung, small intestine, and at a high level in uterus by PCR (Hedblom and Kirkness, 1997) . A hybridization signal from prostate, ovary, placenta, bladder, lung, and small intestine was not observed on the microarray images, but signal in uterus was seen. The dierence we have seen here may be due to detection sensitivity dierence between these two methods. Similar to what we observed with microarray, B709P was expressed in 24% (6 out of 25) of breast tumors and detected in fewer breast tumors than the other three genes. The three normal breast samples did not show any expression, while normal trachea and spleen did show some level of expression for B709P. Hairspeci®c type II keratin showed a very breast tissue speci®c expression pattern and was overexpressed in 52% (13 out of 25) of breast tumors, with very low expression in normal prostate and adrenal gland. Two of the breast tumors showed very high copy numbers. B726P revealed overexpression in 44% (11 out of 25) of breast tumors and had no expression in the normal tissues examined except for one of the three normal breast samples, which has moderate expression compared to breast tumors. The GABA a receptor p subunit real-time PCR pro®le is consistent with its microarray results. It is overexpressed in 36% (9 out of 25) of breast tumors and is also detected at low to moderate levels in normal breast, trachea, and uterus. Other normal tissues tested did not show expression. In summary, consistent with the results from microarray analysis, the quantitative PCR con®rmed that there was dierential expression between breast tumors and other non-breast normal tissues in all genes and that the percentage of breast tumors showing overexpression varies from gene to gene, ranging from 20% to over 50%. Another feature observed from the quantitative PCR is that these four genes are overexpressed in dierent subsets of breast tumors. This result corresponds very well with the previous observations that the genetic variations in breast tumors are diversi®ed (Lopez-Otin and Diamandis, 1998; Jones et al., 1995; Walker et al., 1997) .
The gene expression pro®les of the four genes in metastatic breast tumors were also analysed by real time PCR. The metastatic breast tumors tested were breast tumors metastasized to ovary and to lymph node tissues. Primary breast tumors and normal breast sample were also included in the panel in order to compare gene expression levels between primary tumors and metastatic tumors. As shown in Figure 4 , Figure 1 Microarray analysis of B709P, hair-speci®c type II keratin, B726P, and GABA A receptor p subunit. Pseudo-color images of¯uorescence intensity from 30 pairs of probes were shown. White color represents the highest intensity and the black represents the lowest, as shown at the bottom right of the ®gure. P1/P2 represents the ratio of¯uorescence intensity of probe 1 vs probe 2. Blank P1/P2 ratio means that both P1 and P2 channels are below the detection level of the¯uorescence scanner. Positive P1/P2 value means P1 is larger than P2 and negative P1/P2 value means P2 is larger than P1. BT, breast tumor; Met-BT-LN, metastatic breast tumor to lymph node; HEMC, human epithelial mammary gland cell
Discussion
Gene expression pro®ling and identi®cation of novel genes can provide a signi®cant increase in our understanding of the mechanisms and pathways that regulate the transition from normal growth to malignant proliferation. Furthermore, both tumor-and tissuespeci®c genes are potential candidates for cancer therapy and diagnosis. Coupling subtraction and microarray provides robust and ecient revenue towards the discovery of genes that are dierentially expressed between breast and normal non-breast tissues. PCR-based cDNA subtraction is an ecient and convenient way to obtain large numbers of clones that are already selected for overexpression in targeted tissues. This method eliminates the common housekeeping genes from the library pool, thereby reducing the number of clones to be analysed by microarray from a given target sample. Furthermore, the suppression subtractive hybridization technology utilizes a normalization step that enables the recovery of not only abundant genes but also less abundant genes from the subtracted library. For instance, mammaglobin is a very abundant gene in breast tumors as demonstrated by Northern (Watson et al., 1999) , microarray, and quantitative RT ± PCR (Houghton et al., 2001) . This gene has been identi®ed by PCR-based subtraction, dierential display PCR, and conventional subtraction. On the other hand, B709P and GABA A receptor p subunit are less abundant, and these two genes were not discovered by other approaches such as conventional cDNA subtraction, dierential display PCR, and serological analysis of recombinant tumor cDNA expression libraries. Thus, using PCR-based subtraction to generate clones for microarray analysis has advantages when compared with unsubtracted cDNA libraries or subtracted cDNA libraries generated by the conventional method, which does not have a normalization step and is biased towards the recovery of abundant genes (Xu et al., 2000) . In this study we also pooled three breast tumor samples for the subtraction to increase the probability of identifying genes that are only expressed in a subpopulation of breast cancer patients. The normal tissues used for drivers were preferentially selected to eliminate more eciently nonspeci®c clones that could have expression in vital normal organs. The advantages of cDNA microarray technology are that it has made it possible to analyse thousands of clones simultaneously, and the use of two¯uorescent labels enables a direct comparison of the relative mRNA abundance between two RNA populations. However, compared to other techniques such as Northern hybridization and quantitative RT ± PCR, there are also potential disadvantages associated with microarray. These include the lack of assay sensitivity for rare genes, cross reactivity with homologous sequences, and the fact that it is less quantitative especially for genes that are either rare or abundant. Therefore, quantitative real time PCR was implemented as a con®rmatory assay due to the increased sensitivity and speci®city of this method, as the ®nal step of our antigen discovery process. This provides us with two independent methodologies to verify the mRNA expression pro®le of any particular gene of interest. The panel of tissues used for both microarray and real-time PCR was constructed to ful®l our selection criteria for identifying breast tumor and tissue speci®c genes. In both panels a large number of breast tumors and other vital normal tissues but few normal breast samples were included to assess the tissue distribution of target genes. We used primary tissues for both normal and tumor to re¯ect natural biological processes.
The 62 clones with over threefold overexpression include many known and unknown genes/clones that will be of great interest to breast cancer researchers. Mammaglobin and lipophilin B are two clones with the Figure 2 Nucleotide sequence and the predicted amino acid sequence of B709P Figure 3 Quantitative real time PCR analysis of B709P, hair-speci®c type II keratin, B726P, and GABA A receptor p subunit with primary breast tumors and various normal tissues. The Y-axis represents the copy number for the gene of interest per 1 ng of bactin. Lane 1 ± 25, breast tumors; 26 ± 28, normal breast; 29, normal uterus; 30, normal activated PBMC; 31, normal resting PBMC; 32, normal pancreas; 33, normal live; 34, normal colon; 35, normal spleen; 36, normal esophagus; 37, normal thyroid gland; 38, normal spinal cord; 39, normal bone; 40, normal thymus; 41, normal cartilage; 42, normal lung; 43, normal trachea; 44, normal adrenal gland; 45, normal brain; 46, normal bone marrow; 47, normal small intestine; 48, normal stomach; 49, normal heart; 50, normal kidney; 51, normal prostate; 52 normal skin; 53, normal pituitary gland; 54, normal skeletal muscle; 55, normal ovary; 56, normal retina highest tumor/normal ratio (Table 2) on microarray. Both genes were identi®ed multiple times with microarray. Mammaglobin is a well-documented breast speci®c gene and has been evaluated as a marker for assessing response to therapy or recurrence and for detection of metastatic breast tumor cells (Fleming and Watson, 2000) . Lipophilin B has recently been reported to form a complex with mammaglobin and they are co- Figure 4 Quantitative real time PCR analysis of B709P, hair-speci®c type II keratin, B726P, and GABA A receptor p subunit with metastatic breast tumors, primary breast tumors, and normal breast. The Y-axis represents the copy number for the gene of interest per 1 ng of b-actin. Lane 1, metastatic breast tumor to ovary; 2 ± 19 metastatic breast tumors to lymph node; 20 ± 33 primary breast tumors; 34 normal breast expressed in breast tumors (Colpitts et al., 2001) . Among the 62 clones we also found GATA-3 transcription factor, thrombospondin-1, and AP-2. Studies on the GATA-3 transcription factor gene have indicated that its expression is associated with estrogen receptor expression and is likely to be involved in the regulation of genes that are critical to the hormoneresponsive breast cancers (Hoch et al., 1999) . Thrombospondin-1, which is an extracellular matrix glycoprotein, has been shown to be involved in breast tumor progression (Bertin et al., 1997) . Expression of AP-2 transcription factor in breast cancer has also been reported in the literature (Turner et al., 1998) . This gene is required for normal growth and morphogenesis during mammalian development. Interestingly AP-2 is involved in the regulation of the expression of Her2/ neu and estrogen receptor genes and may play a role in the control of cell growth and dierentiation of breast cancer (Bosher et al., 1995) .
In this study we have demonstrated a high throughput approach to identify genes dierentially expressed in breast tumors by combining SSH subtraction and microarray. The four genes presented in this report, B709P, B726P, hair-speci®c type II keratin and GABA A receptor p subunit, are examples of breast tumor-and tissue-speci®c genes discovered through our methodology. Their mRNA expression pro®les have been demonstrated by cDNA microarray hybridization and quantitative real time PCR analysis. We are currently developing antibodies for each of the four proteins, and will use these antibodies to conduct immunohistochemistry studies to further analyse their expression pattern at the protein level. These genes could potentially be used as targets for antibody and vaccine therapy, and as diagnostic markers for breast cancer. Additionally, understanding the functions of these four genes may lend us greater insight into the mechanisms of tumorigenesis of breast tumor.
Materials and methods
Preparation of total RNA and poly(A)
+ RNA from human tumor and normal tissues All tumor and normal human tissue samples obtained from various clinical sources were accompanied by clinical information and pathological reports, and were histologically con®rmed by pathologists. The tissue samples were snapfrozen in liquid nitrogen and stored at 7808C until use. Total RNAs were isolated from tissue samples using TRIzol total RNA isolation kit (Gibco BRL Life Technology, Inc. Rockville, MD, USA), according to the manufacturer's protocol. Poly(A) + RNAs were extracted from total RNAs using the mRNA Puri®cation Kit from Amersham Pharmacia (Piscataway, NJ, USA).
Subtracted cDNA libraries
Three primary breast tumor mRNA samples were mixed in equal proportion and 2 mg of the poly(A) + RNAs were used to synthesize tester cDNAs. The driver cDNAs were generated from 2 mg of mRNAs containing equal amounts of poly(A) + RNAs from normal breast, brain, liver, pancreas, and peripheral blood mononuclear cells (PBMC). The ®rst and second strand cDNAs were synthesized using reagents included in the PCR-Select cDNA Subtraction kit (Clontech Inc., Palo Alto, CA, USA). The tester and driver cDNAs were blunt-ended with T4 DNA polymerase, and then digested with a mixture of ®ve endonucleases including MluI, MscI, PvuII, SalI, and StuI. A ®lling-in reaction with Klenow fragment was carried out after the digestion to regenerate the blunt ends. The digested tester cDNAs were ligated to adapter 1 and adapter 2 (Clontech Inc., Palo Alto, CA, USA) in separate ligation reactions. The ligation reaction mixtures were incubated overnight at 168C. The subtractive hybridization of adapter-ligated testers with drivers was performed according to the protocol (Clontech), using a tester to driver ratio of 1 : 60. Two rounds of PCR ampli®cation were performed to complete the subtraction and amplify the subtracted cDNA fragments. The ®rst ampli®ca-tion was performed as follows: 5 min adapter extension at 758C, 27 cycles of 948C, 30 s; 668C, 30 s and 728C, 90 s. The second PCR was performed with conditions of 948C, 30 s; 688C, 30 s and 728C, 90 s for 12 cycles. The primers used for PCR were supplied with the Clontech kit.
Dot blot
Plasmid DNAs of 96 randomly selected clones from the subtracted library were spotted onto nylon membranes. Three membranes were probed separately with tester-speci®c probe, driver-speci®c probe, and cDNAs from the subtracted library using the same conditions. The probes were [a-32 P]dCTPlabeled using a random primed DNA labeling kit (Amersham Pharmacia, Piscataway, NJ, USA). Equal amounts of cDNAs were used for probe labeling. All three blots were exposed to Kodak ®lm (X-OMAT) for 16 h.
Cloning and sequencing analysis of the subtracted cDNA library Secondary PCR products generated from the subtracted cDNAs were subcloned into the pCR2.1 TOPO T/A cloning vector using conditions suggested by the manufacturer (Invitrogen, Carlsbad, CA, USA). The ligated cDNAs were then transformed into DH10B electro-competent cells by electroporation (Gibco BRL Life Technology, Inc., Rockville, MD, USA). Ninety-six clones were randomly picked from the library, and plasmid DNAs were prepared using a QIAprep 96 Turbo Miniprep kit (Qiagen Inc. Valencia, CA, USA) according to the manufacturer's protocol. DNA sequencing was performed at Corixa using an ABI377 automated sequencer with M13 forward and reverse primers. DNA homology database searches were performed using the BLAST program (Nakai and Horton, 1999) . cDNA microarray cDNA microarray was performed as described previously (Xu et al., 2000) . Cloned inserts from the subtracted cDNA library were PCR ampli®ed with the pCR2.1 vector speci®c M13 forward and M13 reverse primers. The ampli®ed PCR fragments were analysed visually on a 1.2% agarose gel to ensure the quality and quantity of the DNA prior to the ®nal arraying step. PCR products were arrayed onto glass slides using Incyte patented chemistry. The arrayed cDNAs were hybridized with a 1 : 1 mixture of Cy3-and Cy5-labeled ®rst strand cDNAs generated from 200 ng of poly(A) + RNA from breast tumors and normal tissues (Incyte Pharmaceu-ticals, Palo Alto, CA, USA). Both the hybridization and subsequent imaging were performed by Incyte. Incyte has implemented a 96-well control plate which utilizes yeast genes of 1 kb fragments that are from the inter-ORF regions of the yeast genome and have no homology to the other target sequences arrayed on chips. This control plate was used for determinations of reverse transcription eciency of both Cy3 and Cy5 labeled probes, hybridization eciency of the probes to the array, and the sensitivity of detection. Detailed information on the control plate is posted on the Incyte web site: http://www.incyte.com/reagents/catalog/support/ gem/controls/Qcdoc-cdedit.pdf. The ®nal array images were analysed using Incyte Gemtools software. The¯uorescent intensities between experiments were normalized by using a subset of cDNA clones, which enabled us to compare data between dierent experiments.
Quantitative real-time PCR
The speci®city of genes discovered from cDNA microarray was analysed further using quantitative PCR analysis to con®rm their expression pro®les. Primary and metastatic breast tumors and normal breast tissues along with other normal tissues were tested using quantitative real-time PCR. cDNAs used in the PCR were synthesized from 20 mg of total RNA using Superscript RT (Gibco BRL Life Technology, Rockville, MD, USA) as described by the manufacturer. The total RNAs were treated with DNaseI (Ampli®cation Grade, Gibco BRL Life Technology, Rockville, MD, USA) prior to ®rst-strand synthesis. The real-time PCR was performed using the GeneAmp 1 5700 sequence detection system (PE Biosystems, Foster City, CA, USA). The 5700 system uses SYBR 1 green, a¯uorescent dye that only intercalates with double stranded DNA, and a set of gene speci®c forward and reverse primers. The increase in¯uorescence is monitored during the entire ampli®cation process. The forward primers and reverse primers for the genes of interest are as follows: B709P: Forward, 5'-TGGTGGAAGTGGGCGAA-3'; Reverse, 5'-TCAGTGACAGCGATGAATTAGCTT-3'; Hairspeci®c type II keratin: Forward, 5'-GGTCTGCCGGAAA-TGTTAGG-3'; Reverse, 5'-GCAAGGCAGGGCAGGAA-3'; B726P: Forward, 5'-AACATGCACAAAGAGACCAACGT-3'; Reverse, 5'-TGTTTGTTCACATTATCTTGTTCGTTT-3'; GABA A receptor p subunit: Forward, 5'-AAGCCTCA-GAGTCCTTCCAGTATG-3'; Reverse, 5'-AAATATAAGT-GAAGAAAAAAATTAGTAGATCAACA-3'.
The optimal concentration of primers was determined using a pool of cDNAs from breast tumors. Each PCR reaction was performed in a 25 ml volume that included 2.5 ml of SYBR green buer, 2 ml of cDNA template and 2.5 ml each of the forward and reverse primers for the gene of interest. The cDNAs used for the RT reactions were diluted 1 : 10 for each gene of interest and 1 : 100 for the b-actin control. In order to quantitate the amount of speci®c cDNA (and hence initial mRNA) in the sample, a standard curve was generated for each run using the plasmid DNA containing the gene of interest. Standard curves were generated using the Ct values determined in the real-time PCR which were related to the initial cDNA concentration used in the assay. A set of standard dilutions ranging from 20 ± 2610 6 copies of the gene of interest was used for this purpose. In addition, a standard curve was generated for bactin ranging from 200 fg ± 20 ng. This enabled standardization of initial RNA content of a tissue sample to the amount of b-actin for comparison purposes. The mean copy number for each group of tissues tested was normalized to a constant amount of b-actin, allowing the evaluation of the overexpression levels seen with each of the genes.
Abbreviations EST, expressed sequence tag; GABAp, g-aminobutyrate type A receptor p subunit; ORF, open reading frame; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain reaction; RT, reverse transcription; SSH, suppression subtractive hybridization
